PWMG
EW icon

Prestige Wealth Management Group’s Edwards Lifesciences EW Stock Holding History

Prestige Wealth Management Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.5K Buy
94
+69
+276% +$5.78K ﹤0.01% 471
2026
Q1 		$2K Sell
25
-5
-17% -$412 ﹤0.01% 744
2025
Q4 		$2.56K Sell
30
-301
-91% -$24.7K ﹤0.01% 715
2025
Q3 		$25.7K Hold
331
– – 0.01% 334
2025
Q2 		$25.9K Buy
331
+5
+2% +$373 0.01% 326
2025
Q1 		$23.6K Hold
326
– – 0.01% 327
2024
Q4 		$24.1K Sell
326
-635
-66% -$44.4K 0.01% 335
2024
Q3 		$63.4K Buy
961
+92
+11% +$6.68K 0.01% 231
2024
Q2 		$80.3K Hold
869
– – 0.02% 189
2024
Q1 		$83K Hold
869
– – 0.02% 221
2023
Q4 		$66.3K Sell
869
-5
-0.6% -$348 0.02% 222
2023
Q3 		$60.6K Buy
874
+4
+0.5% +$321 0.01% 223
2023
Q2 		$82.1K Hold
870
– – 0.02% 226
2023
Q1 		$72K Sell
870
-19
-2% -$1.49K 0.02% 212
2022
Q4 		$66.3K Sell
889
-1,166
-57% -$89.9K 0.02% 231
2022
Q3 		$170K Buy
2,055
+112
+6% +$10.8K 0.05% 148
2022
Q2 		$184K Buy
1,943
+1,114
+134% +$115K 0.05% 138
2022
Q1 		$98K Buy
829
+200
+32% +$22.4K 0.02% 185
2021
Q4 		$81K Buy
629
+80
+15% +$9.33K 0.02% 221
2021
Q3 		$63K Sell
549
-100
-15% -$11.4K 0.02% 232
2021
Q2 		$67K Hold
649
– – 0.02% 217
2021
Q1 		$54K Hold
649
– – 0.01% 246
2020
Q4 		$59K Buy
649
+4
+0.6% +$332 0.02% 230
2020
Q3 		$52K Hold
645
– – 0.02% 244
2020
Q2 		$44K Sell
645
-21
-3% -$1.49K 0.02% 237
2020
Q1 		$42K Sell
666
-837
-56% -$60.4K 0.02% 192
2019
Q4 		$117K Buy
1,503
+105
+8% +$8.2K 0.06% 150
2019
Q3 		$102K Buy
1,398
+345
+33% +$24.2K 0.06% 149
2019
Q2 		$65K Buy
1,053
+753
+251% +$45.5K 0.04% 180
2019
Q1 		$19K Buy
300
+204
+213% +$11.6K 0.01% 283
2018
Q4 		$5K Buy
+96
New +$4.86K ﹤0.01% 583

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Prestige Wealth Management Group's EW Position: Q2 2026 in Review

Prestige Wealth Management Group increased its Edwards Lifesciences (EW) stake by 276% in Q2 2026, buying an estimated $5.78K and bringing the position to 94 shares worth $8.5K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

Prestige Wealth Management Group first reported a position in EW in Q4 2018 and has held it in 31 quarters since. The position peaked at $184K in Q2 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Prestige Wealth Management Group held 94 shares of Edwards Lifesciences worth $8.5K as of Q2 2026.
  • Prestige Wealth Management Group bought 69 Edwards Lifesciences shares in Q2 2026, an estimated $5.78K.
  • Edwards Lifesciences made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #471 holding.
  • Prestige Wealth Management Group first reported a position in Edwards Lifesciences in Q4 2018 and has held it in 31 quarters since.
  • Prestige Wealth Management Group's Edwards Lifesciences position peaked at $184K in Q2 2022.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.